NDAINJECTIONINJECTABLE
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OPTIRAY 350 (ioversol) by Guerbet is x-ray contrast activity [moa]. Approved for renal impairment, coronary artery disease, diabetes mellitus and 1 more indications. First approved in 1998.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 350 (ioversol) is a radiographic contrast agent administered by injection to enhance visualization of vascular and organ structures during diagnostic imaging procedures. It is indicated for use in patients with renal impairment, coronary artery disease, diabetes mellitus, and hypothyroidism who require contrast-enhanced imaging. The drug works through X-ray contrast activity, providing opacification to enable clear radiographic visualization.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams should anticipate resource rationalization and transition planning.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Worked on OPTIRAY 350 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.